Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial.

Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 09/2005; 294(5):563-70. DOI: 10.1001/jama.294.5.563
Source: PubMed

ABSTRACT Suicide attempts constitute a major risk factor for completed suicide, yet few interventions specifically designed to prevent suicide attempts have been evaluated.
To determine the effectiveness of a 10-session cognitive therapy intervention designed to prevent repeat suicide attempts in adults who recently attempted suicide.
Randomized controlled trial of adults (N = 120) who attempted suicide and were evaluated at a hospital emergency department within 48 hours of the attempt. Potential participants (N = 350) were consecutively recruited from October 1999 to September 2002; 66 refused to participate and 164 were ineligible. Participants were followed up for 18 months.
Cognitive therapy or enhanced usual care with tracking and referral services.
Incidence of repeat suicide attempts and number of days until a repeat suicide attempt. Suicide ideation (dichotomized), hopelessness, and depression severity at 1, 3, 6, 12, and 18 months.
From baseline to the 18-month assessment, 13 participants (24.1%) in the cognitive therapy group and 23 participants (41.6%) in the usual care group made at least 1 subsequent suicide attempt (asymptotic z score, 1.97; P = .049). Using the Kaplan-Meier method, the estimated 18-month reattempt-free probability in the cognitive therapy group was 0.76 (95% confidence interval [CI], 0.62-0.85) and in the usual care group was 0.58 (95% CI, 0.44-0.70). Participants in the cognitive therapy group had a significantly lower reattempt rate (Wald chi2(1) = 3.9; P = .049) and were 50% less likely to reattempt suicide than participants in the usual care group (hazard ratio, 0.51; 95% CI, 0.26-0.997). The severity of self-reported depression was significantly lower for the cognitive therapy group than for the usual care group at 6 months (P= .02), 12 months (P = .009), and 18 months (P = .046). The cognitive therapy group reported significantly less hopelessness than the usual care group at 6 months (P = .045). There were no significant differences between groups based on rates of suicide ideation at any assessment point.
Cognitive therapy was effective in preventing suicide attempts for adults who recently attempted suicide.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The goal of the National Alliance for Suicide Prevention is to reduce suicide and suicidal behavior by 40% in the next decade. In this paper, a public health approach is applied to suicide prevention to illustrate how reductions in youth suicide and suicidal behavior might be achieved by prioritizing research in two areas: 1) increasing access to primary care based behavioral health interventions for depressed youth and 2) improving continuity of care for youth who present to the emergency department after a suicide attempt. Finally, some scientific, clinical, and methodologic breakthroughs needed to achieve rapid, substantial, and sustained reductions in youth suicide and suicidal behavior are discussed.
    American Journal of Preventive Medicine 08/2014; 47(3S2):s229-S234. · 4.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION Since the introduction of the first antidepressant medications more than 40 years ago, the risk of suicide during drug treatment has been an object of clinical interest. The 1960 textbook 1 Clinical Psychiatry contains the admonishment that "With begin-ning convalescence (following the initiation of treatment with tricyclic antidepres-sants), the risk of suicide once more becomes serious as retardation fades." In the early 1990s the possible contributory role of antidepressants to suicide was revisited as a new class of antidepressants, the selective serotonin reuptake inhibitors (SSRIs), became available. Teichler and colleagues 2 published an article on the emergence of suicidal ideation during treatment with fluoxetine. Following Food and Drug Administration hearings, considerable public debate, and a series of large scale analyses of clinical ABSTRACT This article will review evidence that led the Food and Drug Administration to issue a black-box warning about the risk of suicidality (suicidal thoughts and behavior) in children and adoles-cents during treatment with antidepressants. Reanalysis of data from randomized clinical trials of antidepressants in the pediatric population revealed a significantly greater risk of sui-cidality for drug groups (4%) compared to placebo groups (2%) in a sample of approximately 4,000 subjects. There were no completed suicides. The small but statistically significant risk of suicidality was not restricted to subjects being treated for depression. With respect to efficacy, only three (20%) of 15 antidepressant trials submitted to the FDA for pediatric depression demonstrated superiority of drug over placebo. The essential message of the black-box warning is to remind prescribers and consumers about the importance of monitoring patients closely for adverse behavioral changes during the initiation of (or changes in) antidepressant therapy. Implications of the FDA actions for clinical practice will also be addressed.
  • Source

Full-text (3 Sources)

Available from
Jun 4, 2014